Kronox Lab Sciences Promoters Sell 64.26% Stake for ₹103.22/share
Kronox Lab Sciences promoters are selling 64.26% stake for ₹103.22 per share via SPA dated August 20, 2026. Indo Borax & Chemicals Limited is the acquirer. A mandatory tender offer to public shareholders will follow. This results in a change of promoters and control.
The sale of 64.26% of the company's shares by the promoters represents a substantial change in ownership and control, leading to a significant impact on the company's management, governance, and strategic direction.
The announcement details a significant transaction involving the sale of a majority stake by promoters, which is a material event for the company. The price per share and the mandatory tender offer indicate a structured exit and potential new management, which can be viewed positively.
Kronox Lab Sciences Limited has announced that its promoters, Mr. Ketan Vinodchandra Ramani, Mr. Pritesh Vinodchandra Ramani, and Mr. Jogindersingh Gianchand Jaswal, have executed a Share Purchase Agreement (SPA) on August 20, 2026. They will sell an aggregate of 2,38,44,000 equity shares, representing approximately 64.26% of the company's total paid-up equity share capital, to Indo Borax & Chemicals Limited ("Acquirer") and Zenrock Chemicals Private Limited ("ZCPL").
The SPA transaction is priced at ₹103.22 per equity share. The Acquirer, along with ZCPL (acting in concert), will make a mandatory tender offer to the public shareholders in accordance with SEBI regulations. Upon completion of the transaction, the Acquirer will become the promoter, and ZCPL will be classified as the promoter group. The current promoters will cease to be in control and will be re-classified into the 'public' category.
Significant terms of the SPA include the sale of 64.26% of the company's equity, subject to fulfillment of conditions precedent. The sellers have agreed to non-compete and non-solicit obligations. The remaining 9.95% shareholding of the sellers will be subject to a lock-in period, after which the Acquirer will have a right of first refusal. The Acquirer will appoint three nominee directors to the board, and the current promoters will resign.
What to do with a filing like this
Kronox Lab Sciences Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Kronox Lab Sciences Limited. Read the original for the full detail.